文献速递骨软组织肉瘤与黑色素瘤

黑色素瘤免疫检查点抑制剂治疗中的神经毒性:单中心经验与文献综述

Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.
PubMed 文献 · Ann Oncol · 2017-01-01

该单中心研究纳入2010年9月至2015年12月在皇家马斯登医院接受伊匹木单抗、纳武利尤单抗、帕博利珠单抗或伊匹木单抗联合纳武利尤单抗治疗的晚期黑色素瘤患者352例,共413次免疫治疗疗程,中位随访26.7个月,记录神经毒性10例,总体发生率2.8%,伊匹木单抗联合纳武利尤单抗组发生率为14%。

要点

  • 352例晚期黑色素瘤患者共413次免疫治疗疗程中,神经毒性总体发生率为2.8%。
  • 伊匹木单抗联合纳武利尤单抗治疗中神经毒性发生率为14%。
  • 神经毒性累及中枢和周围神经系统,分级从1级到4级,表现多样。

核心结论

  • 神经毒性并不少见,在伊匹木单抗联合纳武利尤单抗治疗患者中可能更频繁,表现及治疗反应多样,需及时且周全的处理以优化结局。

研究设计与样本

  • 单中心经验及文献综述,纳入2010年9月至2015年12月在皇家马斯登医院接受伊匹木单抗、纳武利尤单抗、帕博利珠单抗或伊匹木单抗联合纳武利尤单抗治疗的晚期黑色素瘤患者,包括已发表临床试验中的患者。
  • 共纳入352例患者的413次免疫治疗疗程,中位随访26.7个月。
  • 对每例患者病历进行回顾并记录神经毒性信息,同时进行系统性检索以汇总现有神经毒性报告。

主要发现

  • 记录到10例神经毒性,影响总体2.8%的患者,分级从1级到4级,累及中枢和周围神经系统。
  • 伊匹木单抗联合纳武利尤单抗治疗中神经毒性发生率为14%。
  • 5例开始使用糖皮质激素的患者中3例有反应。
  • 报告时6例患者已完全恢复。
  • 10例中有7例发现有利的影像学反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase III trials. Immune-related neurological toxicity of varying severity has been reported in the literature. The cumulative incidence of neurotoxicity among ipilimumab, nivolumab and pembrolizumab is reported as <1% in published clinical trials. We aimed to identify the incidence of neurotoxicity in our institution across anti-CTLA4 and anti-PD-1 antibodies, including the combination of ipilimumab with nivolumab. We also review the existing literature and propose an investigation and management algorithm. METHODS: All patients with advanced melanoma treated with ipilimumab, nivolumab, pembrolizumab or the combination of ipilimumab and nivolumab (ipi + nivo), managed at the Royal Marsden Hospital between September 2010 and December 2015, including patients on (published) clinical trials were included. Medical records for each patient were reviewed and information on neurotoxicity recorded. A systematic search strategy was performed to collate existing reports of neurological toxicity. RESULTS: In total, 413 immunotherapy treatment episodes in 352 patients were included, with median follow-up of 26.7 months. Ten cases of neurotoxicity were recorded, affecting 2.8% of patients overall, ranging from grade 1 to 4, affecting both central and peripheral nervous systems. A rate of 14% was noted with ipi + nivo. Three of five patients commenced on corticosteroids responded to these. Six patients had made a full recovery at the time of reporting. A favorable radiological response was found in 7 of the 10 cases. Unusual presentations are described in detail. CONCLUSIONS: Neurological toxicity is not uncommon, and may be more frequent in patients treated with combination ipi + nivo. Patterns of presentation and response to treatment are varied. A prompt and considered approach is required to optimize outcomes in this group of patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol. 2017. PMID: 28426103. doi:10.1093/annonc/mdw558

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。